PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18056475-0	2007	3"-deoxy-3"-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.	alovudine	0-32	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	112-116	
18056475-5	2007	The profound G(1) arrest induced by MEK inhibition in BRAF mutant tumors is associated with a marked decline in thymidine uptake and is therefore potentially detectable in vivo by noninvasive 3"-deoxy-3"-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) imaging.	alovudine	211-226	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	54-58	
23341544-0	2013	3"-Deoxy-3"-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.	alovudine	0-31	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	64-68	
23341544-3	2013	Because constitutive activation of BRAF leads to proliferation in tumors, we explored 3"-deoxy-3"-(18)F-fluorothymidine ((18)F-FLT) PET to noninvasively quantify changes in tumor proliferation that are associated with pharmacologic inhibition of (V600E)BRAF downstream effectors and that precede changes in tumor volume.	alovudine	104-119	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	35-39